阿帕替尼与培美曲塞联合使用对非小细胞肺癌具有抗肿瘤和抗血管生成作用。
The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC.
作者信息
Zhou Ling, Zhang Wenchao, Xiang Yi, Qian Zijun, Zhou Jianping, Ni Lei, Feng Yun, Gao Beili
机构信息
Department of Respiratory Medicine, Rui Jin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200025, China.
Department of Allergy, Henan Provincial People's Hospital, Henan University, Zhengzhou 450000, China.
出版信息
Open Life Sci. 2023 Mar 7;18(1):20220533. doi: 10.1515/biol-2022-0533. eCollection 2023.
Chemotherapy for advanced non-small-cell lung cancer (NSCLC) remains the first treatment choice. Angiogenesis inhibitors are effective for lung cancer treatment. This study explored whether chemotherapy combined with angiogenesis inhibitors could achieve better efficacy in NSCLC. The zebrafish A549 xenograft model was used to investigate the combined effect of apatinib and chemotherapeutic agents in NSCLC. Apatinib combined with pemetrexed demonstrated the highest antitumor effect compared with apatinib combined with gemcitabine or paclitaxel . In the zebrafish A549 xenograft model, apatinib and pemetrexed, alone or in combination, showed significant inhibition of tumor growth. Co-treatment with apatinib and pemetrexed demonstrated the best antitumor effects, suggesting that the combination of apatinib and pemetrexed might be a promising alternative therapy for patients with lung cancer. Apatinib combined with pemetrexed had enhanced antitumor effects compared with either one alone in the zebrafish model of NSCLC.
晚期非小细胞肺癌（NSCLC）的化疗仍然是首选治疗方法。血管生成抑制剂对肺癌治疗有效。本研究探讨了化疗联合血管生成抑制剂是否能在NSCLC中取得更好的疗效。采用斑马鱼A549异种移植模型研究阿帕替尼与化疗药物联合应用于NSCLC的效果。与阿帕替尼联合吉西他滨或紫杉醇相比，阿帕替尼联合培美曲塞显示出最高的抗肿瘤效果。在斑马鱼A549异种移植模型中，阿帕替尼和培美曲塞单独或联合使用均显示出对肿瘤生长的显著抑制作用。阿帕替尼与培美曲塞联合治疗显示出最佳的抗肿瘤效果，这表明阿帕替尼与培美曲塞联合可能是肺癌患者一种有前景的替代治疗方法。在NSCLC斑马鱼模型中，阿帕替尼联合培美曲塞与单独使用任一药物相比，具有增强的抗肿瘤效果。
Zotero 插件